ATE403149T1 - Diagnostische tests auf periostinbasis - Google Patents

Diagnostische tests auf periostinbasis

Info

Publication number
ATE403149T1
ATE403149T1 AT02757081T AT02757081T ATE403149T1 AT E403149 T1 ATE403149 T1 AT E403149T1 AT 02757081 T AT02757081 T AT 02757081T AT 02757081 T AT02757081 T AT 02757081T AT E403149 T1 ATE403149 T1 AT E403149T1
Authority
AT
Austria
Prior art keywords
periostin
diagnostic tests
based diagnostic
human periostin
preeclempsia
Prior art date
Application number
AT02757081T
Other languages
English (en)
Inventor
Lan Bo Chen
Meiru Dai
Hidefumi Sasaki
Daniel Auclair
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE403149T1 publication Critical patent/ATE403149T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
AT02757081T 2001-08-13 2002-08-13 Diagnostische tests auf periostinbasis ATE403149T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31212301P 2001-08-13 2001-08-13

Publications (1)

Publication Number Publication Date
ATE403149T1 true ATE403149T1 (de) 2008-08-15

Family

ID=23209980

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757081T ATE403149T1 (de) 2001-08-13 2002-08-13 Diagnostische tests auf periostinbasis

Country Status (8)

Country Link
US (2) US7087727B2 (de)
EP (1) EP1442295B1 (de)
JP (1) JP2005500059A (de)
AT (1) ATE403149T1 (de)
AU (1) AU2002323120A1 (de)
CA (1) CA2457065A1 (de)
DE (1) DE60227974D1 (de)
WO (1) WO2003016471A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1524524A1 (de) * 1998-12-18 2005-04-20 Scios Inc. Methode zur Detektion und Verwendung von differentiel exprimiertem OSF-2 in der Diagnose von Herzhypertrophie
AU2002323120A1 (en) * 2001-08-13 2003-03-03 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
CA2527571A1 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
PT1806358E (pt) * 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
EP1806587A1 (de) * 2006-01-07 2007-07-11 Université de Liège In-vitro-Verfahren zum Screening zugänglicher biologischer Marker in pathologischen Geweben
EP2128623B1 (de) 2006-02-22 2013-06-26 Philogen S.p.A. Marker für Gefässtumore
KR101560843B1 (ko) * 2007-06-27 2015-10-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
WO2009148184A1 (ja) 2008-06-05 2009-12-10 国立大学法人佐賀大学 特発性間質性肺炎の検出方法
JP5632994B2 (ja) * 2008-12-19 2014-12-03 国立大学法人佐賀大学 非特発性間質性肺炎の治療薬のスクリーニング方法
FR2946349B1 (fr) * 2009-06-03 2013-10-04 Synarc Sas Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine
WO2011068176A1 (ja) * 2009-12-02 2011-06-09 国立大学法人佐賀大学 胆管細胞癌の検出方法および予防・治療剤のスクリーニング方法
JP5555940B2 (ja) * 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
JP2012058048A (ja) * 2010-09-08 2012-03-22 Shino Test Corp ペリオスチン測定の正確性の改善方法
CN105175542B (zh) 2010-12-16 2018-12-18 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
US20140080128A1 (en) 2011-05-18 2014-03-20 Institut National de Ia Sante et de la Recherche Medicale (INSERM) Method for determining whether a subject is at risk of having or developing a chronic kidney disease
EP2754672B1 (de) 2011-09-06 2019-02-27 Shino-Test Corporation Antikörper zur bindung an eine spezifische region von periostin sowie verfahren zur periostinmessung damit
US20140363832A1 (en) * 2011-09-15 2014-12-11 National University Corporation Nagoya University Molecular marker for the early detection of malignant pleural mesothelioma and the methods of its expression analysis using blood and pleural effusion samples
JP5871228B2 (ja) * 2011-10-31 2016-03-01 国立大学法人佐賀大学 慢性副鼻腔炎の検出方法
US9198900B2 (en) 2011-11-10 2015-12-01 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment of peritoneal injury using JAK inhibitors
ES2811060T3 (es) 2013-03-08 2021-03-10 Univ Osaka Anticuerpo contra péptido codificado por exón-21 de periostina y composición farmacéutica para prevenir o tratar enfermedades asociadas a inflamación que contienen el mismo
WO2014153442A2 (en) * 2013-03-21 2014-09-25 The General Hospital Corporation Methods and systems for treatment of ovarian cancer
TWI777194B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
IL300761A (en) 2013-08-05 2023-04-01 Immatics Biotechnologies Gmbh Innovative immunotherapy against several tumors, such as lung cancer, including NSCLC
DK3359210T3 (da) * 2015-10-08 2021-07-12 Univ Geneve Periostin-fragmenter og anvendelse deraf
KR101888193B1 (ko) * 2016-02-19 2018-08-13 이화여자대학교 산학협력단 유방암 전이 진단 지표로서의 혈중 페리오스틴
CN106520771B (zh) * 2016-12-20 2019-02-12 江苏省人民医院 一种长非编码rna及其在诊断/治疗子痫前期中的应用
EP3769089A4 (de) * 2018-03-19 2022-08-03 BioVentures, LLC Periostin-antikörper und verfahren zur verwendung davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05268982A (ja) * 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
CA2175380A1 (en) * 1993-10-29 1995-05-04 Lan Bo Chen A novel tumor marker and novel method of isolating same
WO1998054322A1 (en) * 1997-05-29 1998-12-03 Board Of Regents, The University Of Texas System Osf2/cbfa1 compositions and methods of use
EP1140137A2 (de) * 1998-12-18 2001-10-10 Scios Inc. Methode zur detektion und verwendung von in krankenheitzuständen differentiell exprimierte gene
AU2001233318A1 (en) * 2000-02-03 2001-08-14 Gene Logic, Inc. Modulation of osf-2 in inflammatory and renal diseases
AU2002323120A1 (en) * 2001-08-13 2003-03-03 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays

Also Published As

Publication number Publication date
US7087727B2 (en) 2006-08-08
AU2002323120A1 (en) 2003-03-03
JP2005500059A (ja) 2005-01-06
US20060228763A1 (en) 2006-10-12
EP1442295B1 (de) 2008-07-30
US20030073137A1 (en) 2003-04-17
WO2003016471A3 (en) 2003-08-21
CA2457065A1 (en) 2003-02-27
DE60227974D1 (de) 2008-09-11
EP1442295A4 (de) 2005-08-17
WO2003016471A2 (en) 2003-02-27
EP1442295A2 (de) 2004-08-04

Similar Documents

Publication Publication Date Title
ATE403149T1 (de) Diagnostische tests auf periostinbasis
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
AR037223A1 (es) Anticuerpos bloqueadores de cripto, composiciones que los comprenden, y metodos que los utilizan
EP2360169A3 (de) PSMA Antikörper
DK1587957T3 (da) Genekspressionsmarkør til prognose af brystkræft
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
CY1112101T1 (el) Νευροτροφικοι παραγοντες
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
DE60219419D1 (de) Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
ATE414535T1 (de) Trägerproteine für impfstoffe
CR10212A (es) Modulacion de la formacion osea
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
EP1090294A4 (de) Verfahren um die anwesenheit von krebs in einer probe zu bestimmen durch nachweis der expression eines ssx-gens und peptiden, die von ssx oder ny-eso-1 abgeleitet sind
DE69935782D1 (de) Brustkrebsresistenzprotein (bcrp) und für dieses kodierende dna
AU3392901A (en) Proteins
GB0324656D0 (en) A protein involved in ovarian cancer
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
RS20050577A (en) Compositions and methods for treating cancer using igsf9 and liv-1
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE420365T1 (de) Präparierung von sphären für diagnostische tests
ATE313551T1 (de) Isoliertes nukleinsäuremolekül, das die tumorabstossungs-antigenvorläufer mage- c1 und mage-c2 kodiert und seine verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties